Search results
Binder learned the key value drivers for successful investments and companies in biotech while working as a Principal at Coastview Capital LLC. He has served as an Officer in the US Army, and as a consultant at McKinsey and Company, and has served in a number of line management positions.
3 mar 2002 · Almost a year after starting a local biomedical venture capital firm, retired Amgen Inc. Chairman Gordon Binder is close to raising his first fund, which is set at $100 million, sources say.
Gordon and Adele Binder. SOURCE OF WEALTH: Coastview Capital, Amgen. FUNDING AREAS: Education & Youth, Policy, Arts & Culture, Health & Human Services, Jewish Causes.
Alumni Achievement Awards 2000: Gordon M. Binder Initiatives focus on societal challenges that are too complex for any one discipline or industry to solve alone. ǁ
He is the Founder and Managing Director of Coastview Capital, a private investment firm. [1] [3] [5] He also serves as Chairman of SRU Biosystems. [6] He sits on the Boards of Directors of Acadia Pharmaceuticals , Cellular Genomics, PhRMA and the Biotechnology Industry Organization .
Gordon Binder is a Chairman of Directors at NEUVOGEN based in San Diego, California. Previously, Gordon was a Board Member at Caltech and also hel d positions at American Enterprise Institute, Powerbase, American Cancer Society, Juno Therapeutics, SRU Biosystems, Fornits.
Coastview Capital. Gender Male. Gordon M. Binder is Board of Directors at American Enterprise Institute.
